Radioaerosol Pulmonary Deposition During Asthma Exacerbation Through Noninvasive Ventilation

N/ACompletedNCT01012050

Universidade Federal de Pernambuco39 enrolled

Overview

Despite the physiologic and clinical effects provided by coupling nebulization with noninvasive ventilation in asthma exacerbation, there are few and controversial studies reported in the literature.

Reduced work of breathing, increased oxygenation and increased in expiratory peak flow (EPF) and forced expiratory volume in the first second (FEV1) are benefits of noninvasive ventilation (NV) in the treatment of asthma. Despite these clinical improvements attributed to NV during asthma exacerbations and the well-established effects of nebulization, there are few studies in the literature coupling both therapeutic resources. In addition to this, no studies on scintigraphic analysis of radioaerosol deposition coupled with NV in asthmatics have published. A previous study was published by our group, but involved healthy subjects.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Asthma

Interventions

NVDEVICE

Noninvasive ventilation coupled with nebulization(Nebulization containing salbutamol (2.5mg) and ipratropium bromide (0.25mg)plus oxygen flow in 7Lpm)

NEB groupOTHER

Nebulization containing salbutamol (2.5mg) and ipratropium bromide (0.25mg)plus oxygen flow in 7Lpm

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Clinical diagnosis of moderate to severe asthma (FEV1 \< 60 % of predicted values) * Breathing rate \> 25 bpm * History of asthma for at least 1 year * Duration of current asthma attack of \< 7 days * Reversibility of FEV1 of at least ≤ 10% after the administration of bronchodilator drugs Exclusion Criteria: * Current smoker * Presence of cardiopulmonary disease (COPD, pneumonia, heart failure, myocardial infarction, pneumothorax) * Hyperthermia * Indication of intubation and invasive mechanical ventilation; * Hemodynamic instability (heart rate \> 150 bpm and systolic blood pressure \< 90 mmHg) * Cardiac arrhythmia * Changes in consciousness * Pregnancy * Contraindications to use NV

Locations (1)

Valdecir Castor Galindo Filho

Recife, Pernambuco, Brazil

Outcomes

Primary Outcomes

Cardiopulmonary characteristics

Time frame: 6 months

Secondary Outcomes

Radioaerosol pulmonary index, radioaerosol penetration index and pulmonary clearance.

Time frame: 6 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.